Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Authors:	Molina Jean-Michel,Lamarca Anthony,Andrade-Villanueva Jaime,Clotet Bonaventura,Clumeck Nathan,Liu Ya-Pei,Zhong Lijie,Margot Nicolas,Cheng Andrew K,Chuck Steven L Study Team

Affiliation:	H?pital Saint Louis and University of Paris Diderot, Paris, France. jean-michel.molina@sls.aphp.fr

Abstract:

Keywords:
本文献已被 PubMed 等数据库收录！